Gene Variations in RNA Modification Pathway Linked to Poor Survival After Gastric Cancer Surgery
Genes · 12.08.2026 · 17 (8) · 941
DOI: 10.3390/genes17080941 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, online erschienen am 12.08.2026. Verfasst von Kağan Gökçe und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Faculty of Medicine, Surgical Oncology, Istanbul Okan University, Istanbul 34959, Turkey. Hauptthemen laut MEDLINE: Stomach Neoplasms, Polymorphism, Single Nucleotide, Adenocarcinoma. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: N6-methyladenosine (m6A) RNA modification is a major epitranscriptomic regulator of mRNA stability and translation. Genetic variants in the m6A pathway may influence gastric cancer progression, but their prognostic significance after curative gastrectomy remains uncertain.
Methods
This retrospective study included 226 patients with gastric adenocarcinoma who underwent curative gastrectomy. Single nucleotide polymorphisms in five m6A-related genes (METTL3, METTL14, FTO, ALKBH5, and YTHDF1) were genotyped. Overall survival (OS) and disease-free survival (DFS) were analyzed using Kaplan–Meier and log-rank tests. Multivariable Cox regression was performed after adjustment for age, sex, tumor stage, lymph node status, and adjuvant therapy.
Results
During a median follow-up of 38 months, 78 patients (34.5%) died and 92 (40.7%) experienced recurrence. High-risk m6A genotypes were associated with significantly poorer survival. The 5-year OS was 68.2% in the low-risk group versus 41.5% in the high-risk group (p < 0.001), while 5-year DFS was 61.4% versus 36.8% (p < 0.001). High-risk genotypes independently predicted worse OS (HR 1.87, 95% CI 1.28–2.74; p = 0.001) and DFS (HR 1.94, 95% CI 1.36–2.78; p < 0.001). Patients with the highest genetic risk scores had the poorest outcomes, particularly those with stage III–IV disease.
Conclusion
Genetic variants in the m6A RNA modification pathway are independently associated with poorer survival after curative gastrectomy and may serve as prognostic biomarkers for risk stratification and personalized management in gastric cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, Faculty of Medicine, Surgical Oncology, Istanbul Okan University, Istanbul 34959, Turkey.
- Department of Medical Biology and Genetics, Faculty of Medicine, Istanbul Okan University, Istanbul 34959, Turkey.
- Department of Medical Genetics, Faculty of Medicine, Tehran University of Medical Sciences, Tehran 1416753955, Iran.
ORCID-Profile: Kağan Gökçe
Zitieren
APA
Gökçe, K., & Sheikhvatan, M. (2026). Gene Variations in RNA Modification Pathway Linked to Poor Survival After Gastric Cancer Surgery. Genes, 17(8), 941. https://doi.org/10.3390/genes17080941
Vancouver
Gökçe K, Sheikhvatan M. Gene Variations in RNA Modification Pathway Linked to Poor Survival After Gastric Cancer Surgery. Genes. 2026;17(8):941. doi:10.3390/genes17080941
BibTeX
@article{Gke2026,
author = {Gökçe, Kağan and Sheikhvatan, Mehrdad},
title = {Gene Variations in RNA Modification Pathway Linked to Poor Survival After Gastric Cancer Surgery},
journal = {Genes},
year = {2026},
volume = {17},
number = {8},
pages = {941},
doi = {10.3390/genes17080941}
}
EUVIMED